Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

ON DEMAND - Developing Products by the FDA Animal Rule: Working with FDA and Real World Challenges

Session Chair(s)

David J Pepperl, PhD

David J Pepperl, PhD

Senior Consultant and Nonclinical Group Leader

Biologics Consulting, United States

Using the animal rule approach, sponsors must generate clinically meaningful data in a biologically relevant animal model. Given the many challenges posed in bridging animal data to humans, the Animal Rule poses significant challenges for sponsors. This session will provide an introduction and overview of the Animal Rule, its nuances, intended use and role in clinical development when human clinical trials are either not feasible or ethical. The speakers will address different clinical strategies using the Animal Rule as well as various challenges and incentives associated with this approach. Specific “real world” case studies using the animal rule will also be presented for audience consideration.

Learning Objective : Describe key provisions of the FDA Animal Rule and current guidance as they relate to development of both drugs and biologics when Human clinical trials are not ethical or feasible; Identify key themes in development of drugs and biologics under the Animal Rule; Recognize key incentives and challenges of the Animal Rule pathway; Define several “real world” examples as well as benefits garnered and key challenges faced in developing novel drugs and biologics under the Animal Rule.

Speaker(s)

Larry J Davis, PharmD

The FDA Animal Rule: FDA Guidance, Product Approvals, and Remaining Challenges

Larry J Davis, PharmD

Keck Graduate Institute, School of Applied Life Sciences, United States

Professor of Practice, Clinical and Regulatory Affairs

Michael  Merchlinsky, PhD

Approval of Medical Countermeasures Under the FDA Animal Rule: TPOXX, a Therapeutic Antiviral Against Smallpox

Michael Merchlinsky, PhD

BARDA, United States

Scientific Program Manager

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.